Michael D Taylor

List of Publications by Citations

413 papers	35,564 citations	90 h-index	179 g-index
448 ext. papers	43,767 ext. citations	12.8 avg, IF	6.6 L-index

#	Paper	IF	Citations
413	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37	24.3	1243
412	Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathologica*, **2012**, 123, 465-72	14.3	1167
411	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
410	Medulloblastoma comprises four distinct molecular variants. *Journal of Clinical Oncology*, **2011**, 29, 1408-14	2.2	919
409	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathologica*, **2012**, 123, 473-84	14.3	678
408	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. *Cancer Cell*, **2015**, 27, 728-43	24.3	672
407	Radial glia cells are candidate stem cells of ependymoma. *Cancer Cell*, **2005**, 8, 323-35	24.3	670
406	Mutations in SUFU predispose to medulloblastoma. *Nature Genetics*, **2002**, 31, 306-10	36.3	636
405	Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5	50.4	623
404	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600
403	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
402	The genetic landscape of the childhood cancer medulloblastoma. *Science*, **2011**, 331, 435-9	33.3	576
401	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*, **2012**, 488, 106-10	50.4	552
400	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32	36.3	550
399	Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. *Journal of Clinical Oncology*, **2006**, 24, 1924-31	2.2	543
398	Intertumoral Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell*, **2017**, 31, 737-754.e6	24.3	511
397	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072	36.2	483

396	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472
395	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
394	Medulloblastomics: the end of the beginning. *Nature Reviews Cancer*, **2012**, 12, 818-34	31.3	443
393	Comprehensive Analysis of Hypermutation in Human Cancer. *Cell*, **2017**, 171, 1042-1056.e10	56.2	417
392	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57	24.3	395
391	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. *Nature*, **2014**, 511, 428-34	50.4	377
390	Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors: a prospective trial of 200 cases. *Journal of Neurosurgery*, **1999**, 90, 35-41	3.2	370
389	Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. *Nature Genetics*, **2009**, 41, 465-72	36.3	337
388	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. *Acta Neuropathologica*, **2016**, 131, 821-31	14.3	324
387	Clonal selection drives genetic divergence of metastatic medulloblastoma. *Nature*, **2012**, 482, 529-33	50.4	322
386	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, **2016**, 29, 379-393	24.3	319
385	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. *Nature* , **2014**, 510, 537-41	50.4	296
384	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. *Journal of Clinical Oncology*, **2013**, 31, 2927-35	2.2	290
383	YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. *Genes and Development*, **2009**, 23, 2729-41	12.6	286
382	Challenges to curing primary brain tumours. *Nature Reviews Clinical Oncology*, **2019**, 16, 509-520	19.4	284
381	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. *Nature*, **2010**, 466, 632-6	50.4	283
380	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. *Cell*, **2013**, 153, 1064-79	56.2	276
379	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. *Acta Neuropathologica*, **2012**, 123, 615-26	14.3	265

378	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature*, **2017**, 543, 122-125	50.4	260
377	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. *Nature Genetics*, **2015**, 47, 257-62	36.3	253
376	The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. *Cancer Research*, **2009**, 69, 3249-55	10.1	248
375	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7	21.7	226
374	The clinical implications of medulloblastoma subgroups. *Nature Reviews Neurology*, **2012**, 8, 340-51	15	217
373	An animal model of MYC-driven medulloblastoma. *Cancer Cell*, **2012**, 21, 155-67	24.3	217
372	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. *PLoS ONE*, **2009**, 4, e4998	3.7	208
371	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
370	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. *Acta Neuropathologica*, **2017**, 133, 5-12	14.3	202
369	Medulloblastoma. *Nature Reviews Disease Primers*, **2019**, 5, 11	51.1	202
368	Cytogenetic prognostication within medulloblastoma subgroups. *Journal of Clinical Oncology*, **2014**, 32, 886-96	2.2	199
367	Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. *Nature*, **2017**, 549, 227-232	50.4	197
366	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. *Acta Neuropathologica*, **2013**, 125, 913-6	14.3	194
365	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187
364	BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. *Journal of Clinical Oncology*, **2015**, 33, 1015-22	2.2	187
363	Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. *Cancer Cell*, **2014**, 26, 33-47	24.3	181
362	Disrupting the CD47-SIRP□anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. *Science Translational Medicine*, **2017**, 9,	17.5	179
361	Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. *Cancer Cell*, **2009**, 16, 533-46	24.3	178

360	Adult medulloblastoma comprises three major molecular variants. *Journal of Clinical Oncology*, **2011**, 29, 2717-23	2.2	176
359	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. *Lancet Oncology, The*, **2013**, 14, 534-42	21.7	169
358	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncology, The*, **2018**, 19, 785-798	21.7	159
357	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. *Acta Neuropathologica*, **2011**, 122, 231-40	14.3	159
356	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. *Journal of Clinical Oncology*, **2017**, 35, 2934-2941	2.2	153
355	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica*, **2014**, 128, 279-89	14.3	152
354	HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. *Clinical Cancer Research*, **2010**, 16, 3240-52	12.9	152
353	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. *Nature*, **2019**, 572, 67-73	50.4	149
352	Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. *American Journal of Human Genetics*, **2000**, 66, 1403-6	11	149
351	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. *Cancer Cell*, **2016**, 29, 311-323	24.3	146
350	Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. *Journal of Clinical Oncology*, **2014**, 32, 1760-8	2.2	141
349	Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. *Cancer Cell*, **2012**, 21, 601-613	24.3	141
348	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell*, **2016**, 30, 891-908	24.3	135
347	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. *Nature Genetics*, **2014**, 46, 39-44	36.3	131
346	Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. *Oncogene*, **2004**, 23, 3444-53	9.2	131
345	Pleiotropic role for MYCN in medulloblastoma. *Genes and Development*, **2010**, 24, 1059-72	12.6	128
344	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. *Acta Neuropathologica*, **2013**, 125, 373-84	14.3	126
343	FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. *Journal of Clinical Oncology*, **2011**, 29, 3852-61	2.2	125

342	Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. *Journal of Clinical Oncology*, **2010**, 28, 1345-50	2.2	124
341	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. *Lancet Oncology, The*, **2015**, 16, 569-82	21.7	117
340	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. *Nature*, **2018**, 553, 101-105	50.4	116
339	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
338	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. *Acta Neuropathologica*, **2017**, 134, 705-714	14.3	114
337	Awake craniotomy for removal of intracranial tumor: considerations for early discharge. *Anesthesia and Analgesia*, **2001**, 92, 89-94	3.9	114
336	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. *Journal of Clinical Oncology*, **2016**, 34, 2468-77	2.2	113
335	Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. *Journal of Neurosurgery*, **2000**, 93, 437-48	3.2	112
334	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. *Acta Neuropathologica*, **2018**, 136, 211-226	14.3	111
333	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. *Acta Neuropathologica*, **2014**, 128, 291-303	14.3	111
332	Molecular subgroups of medulloblastoma. *Expert Review of Neurotherapeutics*, **2012**, 12, 871-84	4.3	103
331	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. *Cancer Cell*, **2017**, 32, 295-309.e12	24.3	100
330	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. *Nature Communications*, **2019**, 10, 4343	17.4	95
329	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. *Acta Neuropathologica*, **2013**, 125, 359-71	14.3	95
328	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. *Acta Neuropathologica*, **2014**, 128, 137-49	14.3	93
327	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. *Cancer Cell*, **2020**, 37, 569-583.e5	24.3	92
326	MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. *Journal of Biological Chemistry*, **2013**, 288, 1918-28	5.4	91
325	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. *Acta Neuropathologica*, **2019**, 138, 309-326	14.3	90

324	Medulloblastoma: From Myth to Molecular. *Journal of Clinical Oncology*, **2017**, 35, 2355-2363	2.2	90
323	Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. *Neurosurgery*, **2000**, 47, 888-901	3.2	89
322	OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. *Cancer Research*, **2010**, 70, 181-91	10.1	88
321	Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 1541-8	4	87
320	Clinical and neuroanatomical predictors of cerebellar mutism syndrome. *Neuro-Oncology*, **2012**, 14, 1294-1303	1	87
319	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. *Neuro-Oncology*, **2016**, 18, 291-7	1	86
318	TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. *Journal of Clinical Oncology*, **2010**, 28, 5188-96	2.2	83
317	The G protein □subunit G□ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. *Nature Medicine*, **2014**, 20, 1035-42	50.5	82
316	An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. *Cancer Research*, **2008**, 68, 9945-53	10.1	82
315	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. *Cancer Cell*, **2016**, 29, 394-406	24.3	81
314	Spatial heterogeneity in medulloblastoma. *Nature Genetics*, **2017**, 49, 780-788	36.3	80
313	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. *Cancer Research*, **2016**, 76, 4708-19	10.1	80
312	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. *Oncotarget*, **2014**, 5, 2355-71	3.3	80
311	The U1 spliceosomal RNA is recurrently mutated in multiple cancers. *Nature*, **2019**, 574, 712-716	50.4	79
310	EPEN-12. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS. *Neuro-Oncology*, **2019**, 21, ii79-ii80	1	78
309	MEDU-13. CONVERGENCE OF BMI1 AND CHD7 ON ERK SIGNALLING IN MEDULLOBLASTOMA. *Neuro-Oncology*, **2017**, 19, iv40-iv40	1	78
308	CMS-09BEHAVIOR AND TEMPERAMENT IN CHILDREN TREATED FOR PEDIATRIC MEDULLOBLASTOMA WITH POSTOPERATIVE CEREBELLAR MUTISM SYNDROME. *Neuro-Oncology*, **2016**, 18, iii17.4-iii17	1	78
307	MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. *Neuro-Oncology*, **2015**, 17, v144.1-v144	1	78

306	CS-01THE PHOSPHORYLATION OF ATOH1 LEADS TO ITS DEGRADATION MEDIATED BY THE E3 UBIQUITIN LIGASE HUWE1 IN GRANULE NEURON PROGENITORS. *Neuro-Oncology*, **2014**, 16, v51-v51	1	78
305	GE-16 * JAPANESE PEDIATRIC MOLECULAR NEURO-ONCOLOGY GROUP (JPMNG): ESTABLISHMENT OF A NATIONWIDE MOLECULAR DIAGNOSTIC NETWORK FOR PEDIATRIC MALIGNANT BRAIN TUMORS IN JAPAN. *Neuro-Oncology*, **2014**, 16, v99-v100	1	78
304	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN□ HAEMATOLOGY/ONCOLOGY GROUP. *Neuro-Oncology*, **2020**, 22, iii315-iii315	1	78
303	MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE. *Neuro-Oncology*, **2020**, 22, iii400-iii400	1	78
302	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. *Neuro-Oncology*, **2020**, 22, iii377-iii377	1	78
301	TBIO-15. MODELING DEVELOPMENTAL GENE EXPRESSION DYNAMICS AT CELLULAR RESOLUTION TO INTERPRET PEDIATRIC BRAIN TUMOR TRANSCRIPTIONAL PROGRAMS. *Neuro-Oncology*, **2020**, 22, iii469-iii469	1	78
300	42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM. *Neuro-Oncology Advances*, **2020**, 2, ii8-ii8	0.9	78
299	Recurrent noncoding U1□snRNA mutations drive cryptic splicing in SHH medulloblastoma. *Nature*, **2019**, 574, 707-711	50.4	78
298	EPEN-23. MOLECULAR HETEROGENEITY AMONG PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. *Neuro-Oncology*, **2018**, 20, i77-i78	1	78
297	MBRS-14. REGULATION OF MEDULLOBLASTOMA IMMUNOGENICITY BY TP53 AND TNF ALPHA. *Neuro-Oncology*, **2018**, 20, i131-i131	1	78
296	Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. *Journal of the American Heart Association*, **2015**, 4,	6	76
295	Molecular diagnostics of CNS embryonal tumors. *Acta Neuropathologica*, **2010**, 120, 553-66	14.3	72
294	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. *Pediatric Blood and Cancer*, **2016**, 63, 1527-34	3	71
293	Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. *Cancer Research*, **2013**, 73, 6734-44	10.1	70
292	The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. *Cancer Cell*, **2003**, 3, 37-50	24.3	69
291	Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. *Journal of Clinical Oncology*, **2020**, 38, 454-461	2.2	69
290	Roadmap for the Emerging Field of Cancer Neuroscience. *Cell*, **2020**, 181, 219-222	56.2	68
289	Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. *Oncogene*, **2004**, 23, 4577-83	9.2	66

288	An epigenetic gateway to brain tumor cell identity. *Nature Neuroscience*, **2016**, 19, 10-9	25.5	65
287	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. *Cancer Cell*, **2015**, 28, 715-729	24.3	64
286	Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clinical Cancer Research*, **2015**, 21, 184-92	12.9	63
285	The genetic and epigenetic basis of ependymoma. *Childs Nervous System*, **2009**, 25, 1195-201	1.7	63
284	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. *Journal of Clinical Investigation*, **2019**, 129, 223-229	15.9	62
283	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. *Cancer Cell*, **2018**, 34, 379-395.e7	24.3	62
282	Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. *BMC Cancer*, **2012**, 12, 80	4.8	61
281	Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. *Cancer Research*, **2010**, 70, 8003-14	10.1	61
280	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. *Nature Medicine*, **2020**, 26, 720-731	50.5	60
279	The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. *American Journal of Pathology*, **2012**, 181, 1762-72	5.8	60
278	Targeting the enhancer of zeste homologue 2 in medulloblastoma. *International Journal of Cancer*, **2012**, 131, 1800-9	7.5	60
277	Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. *Journal of Neurosurgery: Pediatrics*, **2010**, 5, 615-21	2.1	59
276	Rapid diagnosis of medulloblastoma molecular subgroups. *Clinical Cancer Research*, **2011**, 17, 1883-94	12.9	59
275	Shh signaling protects Atoh1 from degradation mediated by the E3 ubiquitin ligase Huwe1 in neural precursors. *Developmental Cell*, **2014**, 29, 649-61	10.2	58
274	Medulloblastoma subgroups remain stable across primary and metastatic compartments. *Acta Neuropathologica*, **2015**, 129, 449-57	14.3	58
273	Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4325-34	11.5	58
272	The genetics of pediatric brain tumors. *Current Neurology and Neuroscience Reports*, **2010**, 10, 215-23	6.6	58
271	Stalled developmental programs at the root of pediatric brain tumors. *Nature Genetics*, **2019**, 51, 1702-1713	38.3	58

270	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 515-27	14.3	57
269	MR Imaging-Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma. *American Journal of Neuroradiology*, **2019**, 40, 154-161	4.4	57
268	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. *Nature Neuroscience*, **2015**, 18, 1236-46	25.5	56
267	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 529-38	14.3	56
266	Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. *Neoplasia*, **2010**, 12, 20-7	6.4	56
265	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. *Journal of Clinical Oncology*, **2016**, 34, 4161-4170	2.2	56
264	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. *Genes and Development*, **2012**, 26, 1780-96	12.6	54
263	Medulloblastoma in the age of molecular subgroups: a review. *Journal of Neurosurgery: Pediatrics*, **2019**, 24, 353-363	2.1	53
262	Heterogeneity within the PF-EPN-B ependymoma subgroup. *Acta Neuropathologica*, **2018**, 136, 227-237	14.3	52
261	Hypermutation of the inactive X chromosome is a frequent event in cancer. *Cell*, **2013**, 155, 567-81	56.2	50
260	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. *Cancer Research*, **2010**, 70, 8199-210	10.1	50
259	Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. *Cancer Cell*, **2019**, 36, 302-318.e7	24.3	49
258	Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. *Childs Nervous System*, **2015**, 31, 1661-76	1.7	48
257	BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. *Acta Neuropathologica*, **2016**, 131, 147-50	14.3	48
256	CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. *Cancer Research*, **2012**, 72, 122-32	10.1	48
255	Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. *Molecular Cancer*, **2014**, 13, 72	42.1	47
254	FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. *Cancer Genetics*, **2011**, 204, 577-88	2.3	47
253	Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. *Cancer Research*, **2015**, 75, 134-46	10.1	46

252	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. *Cell*, **2018**, 172, 1050-1062.e14	36.2	46
251	The molecular landscape of ETMR at diagnosis and relapse. *Nature*, **2019**, 576, 274-280	50.4	46
250	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. *Nature Communications*, **2017**, 8, 186	17.4	45
249	Molecular pathogenesis of childhood brain tumors. *Journal of Neuro-Oncology*, **2004**, 70, 203-15	4.8	45
248	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. *Oncotarget*, **2016**, 7, 28169-82	3.3	44
247	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. *EMBO Journal*, **2016**, 35, 2192-2212	13	44
246	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. *Acta Neuropathologica Communications*, **2018**, 6, 134	7.3	44
245	FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells. *Stem Cells*, **2013**, 31, 1266-77	5.8	43
244	Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. *Cancer Research*, **2013**, 73, 6310-22	10.1	43
243	ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. *Cancer Discovery*, **2014**, 4, 1198-213	24.4	43
242	Preclinical target validation using patient-derived cells. *Nature Reviews Drug Discovery*, **2015**, 14, 149-50	64.1	40
241	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. *Cell Reports*, **2019**, 29, 2338-2354.e7	10.6	40
240	Medulloblastoma molecular dissection: the way toward targeted therapy. *Current Opinion in Oncology*, **2013**, 25, 674-81	4.2	40
239	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. *Neurosurgical Focus*, **2010**, 28, E6	4.2	40
238	Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. *Cancer Research*, **2012**, 72, 636-44	10.1	40
237	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. *Cell*, **2020**, 181, 1329-1345.e24	36.2	40
236	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. *Cancer Cell*, **2019**, 36, 51-67.e7	24.3	39
235	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. *Acta Neuropathologica*, **2014**, 128, 853-62	14.3	38

234	Functional genomics identifies drivers of medulloblastoma dissemination. *Cancer Research*, **2012**, 72, 4944-53	10.1	38
233	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. *Molecular Cancer Therapeutics*, **2015**, 14, 2560-8	6.1	37
232	Neurosurgical management of extraaxial central nervous system infections in children. *Journal of Neurosurgery: Pediatrics*, **2011**, 7, 441-51	2.1	37
231	Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. *Science Signaling*, **2018**, 11,	8.8	37
230	Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. *Journal of Neurosurgery: Pediatrics*, **2015**, 15, 236-42	2.1	35
229	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. *Clinical Cancer Research*, **2015**, 21, 3750-8	12.9	35
228	Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. *Childs Nervous System*, **2014**, 30, 979-90	1.7	35
227	The Shh receptor Boc promotes progression of early medulloblastoma to advanced tumors. *Developmental Cell*, **2014**, 31, 34-47	10.2	35
226	Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. *Journal of Neurosurgery: Pediatrics*, **2008**, 1, 305-13	2.1	35
225	Mouse models of medulloblastoma. *Chinese Journal of Cancer*, **2011**, 30, 442-9		35
224	Nestin expression identifies ependymoma patients with poor outcome. *Brain Pathology*, **2012**, 22, 848-66	6	34
223	Basal Suppression of the Sonic Hedgehog Pathway by the G-Protein-Coupled Receptor Gpr161 Restricts Medulloblastoma Pathogenesis. *Cell Reports*, **2018**, 22, 1169-1184	10.6	33
222	Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. *Pediatric Blood and Cancer*, **2014**, 61, 1190-4	3	33
221	Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation. *Cancer Research*, **2017**, 77, 3217-3230	10.1	32
220	The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. *Neuro-Oncology*, **2017**, 19, 1217-1227	1	32
219	Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes. *Neoplasia*, **2013**, 15, 384-98	6.4	32
218	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. *Acta Neuropathologica Communications*, **2014**, 2, 174	7.3	32
217	The epigenetics of brain tumors. *Methods in Molecular Biology*, **2012**, 863, 139-53	1.4	32

216	Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. *Cancer Research*, **2009**, 69, 7224-34	10.1	32
215	Transcriptional profiling of medulloblastoma in children. *Journal of Neurosurgery*, **2003**, 99, 534-41	3.2	32
214	Executive function in paediatric medulloblastoma: The role of cerebrocerebellar connections. *Journal of Neuropsychology*, **2017**, 11, 174-200	2.6	31
213	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. *Cell Stem Cell*, **2019**, 25, 433-446.e7	18	31
212	High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. *Genome Research*, **2019**, 29, 1211-1222	9.7	31
211	Medulloblastoma in a child with Rubenstein-Taybi Syndrome: case report and review of the literature. *Pediatric Neurosurgery*, **2001**, 35, 235-8	0.9	31
210	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. *Nature Communications*, **2019**, 10, 5829	17.4	31
209	Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. *Pediatric Blood and Cancer*, **2014**, 61, 107-15	3	30
208	ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma. *Experimental Hematology and Oncology*, **2013**, 2, 26	7.8	30
207	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. *Acta Neuropathologica*, **2014**, 128, 863-77	14.3	30
206	Molecular genetics of ependymoma. *Chinese Journal of Cancer*, **2011**, 30, 669-81		30
205	Review of molecular classification and treatment implications of pediatric brain tumors. *Current Opinion in Pediatrics*, **2018**, 30, 3-9	3.2	30
204	A homing system targets therapeutic T cells to brain cancer. *Nature*, **2018**, 561, 331-337	50.4	30
203	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. *Childs Nervous System*, **2017**, 33, 1047-1051	1.7	29
202	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. *Cell*, **2020**, 183, 1617-1633.e22	56.2	29
201	Genetic and molecular alterations across medulloblastoma subgroups. *Journal of Molecular Medicine*, **2015**, 93, 1075-84	5.5	27
200	Rapid determination of medulloblastoma subgroup affiliation with mass spectrometry using a handheld picosecond infrared laser desorption probe. *Chemical Science*, **2017**, 8, 6508-6519	9.4	27
199	Differential patterns of metastatic dissemination across medulloblastoma subgroups. *Journal of Neurosurgery: Pediatrics*, **2018**, 21, 145-152	2.1	27

198	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. *Cancer*, **2019**, 125, 1867-1876	6.4	26
197	Evasion of Cell Senescence Leads to Medulloblastoma Progression. *Cell Reports*, **2016**, 14, 2925-37	10.6	26
196	Incorporation of C-1 lateral mass screws in occipitocervical and atlantoaxial fusions for children 8 years of age or younger. Technical note. *Journal of Neurosurgery: Pediatrics*, **2007**, 107, 178-83	2.1	26
195	Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. *JAMA Network Open*, **2019**, 2, e192597	10.4	25
194	Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. *Developmental Cell*, **2018**, 44, 709-724.e6	10.2	25
193	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility. *Journal of Clinical Oncology*, **2016**, 34, 3697-3704	2.2	25
192	Normal and oncogenic roles for microRNAs in the developing brain. *Cell Cycle*, **2009**, 8, 4049-54	4.7	25
191	Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression. *International Journal of Cancer*, **2014**, 134, 21-31	7.5	24
190	Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. *Cancer Genetics*, **2012**, 205, 220-31	2.3	24
189	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. *Nature Communications*, **2018**, 9, 4121	17.4	24
188	The clinical importance of medulloblastoma extent of resection: a systematic review. *Journal of Neuro-Oncology*, **2018**, 139, 523-539	4.8	24
187	Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas. *Journal of Neurosurgery: Pediatrics*, **2015**, 16, 126-33	2.1	23
186	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. *JCO Precision Oncology*, **2020**, 4,	3.6	23
185	Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma. *Acta Neuropathologica Communications*, **2014**, 2, 85	7.3	23
184	Subgroup-specific alternative splicing in medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 485-499	14.3	23
183	Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma. *Developmental Cell*, **2019**, 48, 167-183.e5	10.2	23
182	Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. *Nature Neuroscience*, **2020**, 23, 842-853	25.5	22
181	p53 and Meduloblastoma. *Cold Spring Harbor Perspectives in Medicine*, **2015**, 6, a026278	5.4	22

180	Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion. *Acta Neuropathologica Communications*, **2014**, 2, 10	7.3	22
179	Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma. *Cancer Research*, **2013**, 73, 5381-90	10.1	22
178	Retrospective family study of childhood medulloblastoma. *American Journal of Medical Genetics, Part A*, **2005**, 134, 399-403	2.5	22
177	Posterior fossa ependymoma: current insights. *Childs Nervous System*, **2015**, 31, 1699-706	1.7	21
176	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. *Acta Neuropathologica Communications*, **2018**, 6, 48	7.3	21
175	Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. *Journal of Neurosurgery*, **2014**, 121, 1434-45	3.2	21
174	An epigenetic therapy for diffuse intrinsic pontine gliomas. *Nature Medicine*, **2014**, 20, 1378-9	50.5	21
173	SnapShot: Medulloblastoma. *Cancer Cell*, **2014**, 26, 940-940.e1	24.3	21
172	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 3392-3397	11.5	20
171	Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. *Oncotarget*, **2015**, 6, 21718-29	3.3	20
170	MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. *American Journal of Neuroradiology*, **2018**, 39, 949-955	4.4	19
169	ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. *Cancer Research*, **2019**, 79, 4057-4071	10.1	19
168	MyoD is a tumor suppressor gene in medulloblastoma. *Cancer Research*, **2013**, 73, 6828-37	10.1	19
167	Canonical TGF-pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development. *Brain Pathology*, **2013**, 23, 178-91	6	19
166	Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. *Cell Reports*, **2017**, 21, 2772-2784	10.6	19
165	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. *Cancer Discovery*, **2021**, 11, 1176-1191	24.4	19
164	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. *Oncotarget*, **2015**, 6, 3359-74	3.3	19
163	Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma. *Journal of Neurosurgery: Pediatrics*, **2016**, 18, 29-40	2.1	19

162	Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time. *Annual Review of Genomics and Human Genetics*, **2017**, 18, 143-166	9.7	18
161	Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales. *Cancer Research*, **2019**, 79, 2426-2434	10.1	18
160	DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. *Developmental Cell*, **2020**, 54, 455-470.e5	10.2	18
159	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 696-702	3.1	18
158	Emerging insights into the ependymoma epigenome. *Brain Pathology*, **2013**, 23, 206-9	6	18
157	De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival. *Pediatric Blood and Cancer*, **2014**, 61, 1300-4	3	18
156	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. *Childs Nervous System*, **2012**, 28, 521-32	1.7	18
155	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. *Childs Nervous System*, **2011**, 27, 1243-9	1.7	18
154	WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma. *Neurosurgery*, **2012**, 70, 1003-10; discussion 1010	3.2	18
153	The hPMS2 exon 5 mutation and malignant glioma. Case report. *Journal of Neurosurgery*, **1999**, 90, 946-50	3.2	18
152	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. *Oncotarget*, **2015**, 6, 2709-24	3.3	18
151	Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes. *Oncotarget*, **2015**, 6, 38881-900	3.3	18
150	TGF-Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma. *Cell Reports*, **2018**, 23, 3798-3812.e8	10.6	18
149	Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. *Cancer Research*, **2019**, 79, 905-917	10.1	17
148	Visualization and segmentation of reciprocal cerebrocerebellar pathways in the healthy and injured brain. *Human Brain Mapping*, **2015**, 36, 2615-28	5.9	17
147	Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity. *Cancer Research*, **2014**, 74, 4864-74	10.1	17
146	Proteomic profiling of high risk medulloblastoma reveals functional biology. *Oncotarget*, **2015**, 6, 14584-95	3.3	17
145	Medulloblastoma in the Molecular Era. *Journal of Korean Neurosurgical Society*, **2018**, 61, 292-301	2.3	17

144	Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. *ELife*, **2016**, 5,	8.9	17
143	Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. *American Journal of Neuroradiology*, **2020**, 41, 1718-1725	4.4	17
142	MPS1 kinase as a potential therapeutic target in medulloblastoma. *Oncology Reports*, **2016**, 36, 2633-2640	3.5	17
141	Treatment implications of posterior fossa ependymoma subgroups. *Chinese Journal of Cancer*, **2016**, 35, 93		17
140	Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. *Neuropathology*, **2018**, 38, 475-483	2	17
139	CD271 Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. *Cancer Research*, **2018**, 78, 4745-4759	10.1	16
138	Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis. *PLoS ONE*, **2014**, 9, e113489	3.7	16
137	G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. *Acta Neuropathologica Communications*, **2013**, 1, 66	7.3	16
136	Posterior fossa ependymomas: new radiological classification with surgical correlation. *Childs Nervous System*, **2010**, 26, 1765-72	1.7	16
135	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. *Neuro-Oncology*, **2019**, 21, 547-557	1	16
134	Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. *BMC Cancer*, **2019**, 19, 571	4.8	15
133	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. *Clinical Cancer Research*, **2018**, 24, 1355-1363	12.9	15
132	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. *BMC Cancer*, **2016**, 16, 115	4.8	15
131	Molecular genetics of pineal region neoplasms. *Journal of Neuro-Oncology*, **2001**, 54, 219-38	4.8	15
130	Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth. *Journal of Neurosurgery: Pediatrics*, **2019**, 1-9	2.1	15
129	Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. *Genes Chromosomes and Cancer*, **2017**, 56, 639-650	5	14
128	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. *Cancer Research*, **2019**, 79, 2111-2123	10.1	14
127	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. *Neuro-Oncology*, **2020**, 22, 1474-1483	1	14

126	Genetics of choroid plexus tumors. *Neurosurgical Focus*, **2006**, 20, E10	4.2	14
125	The history of neurosurgery at the Hospital for Sick Children in Toronto. *Neurosurgery*, **2007**, 61, 612-24; discussion 624-5	3.2	14
124	Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective. *Journal of Neuro-Oncology*, **2001**, 51, 205-18	4.8	14
123	H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. *Cancer Discovery*, **2020**, 10, 1968-1987	24.4	14
122	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. *Journal of Neuro-Oncology*, **2019**, 142, 39-48	4.8	14
121	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. *Neuro-Oncology*, **2021**, 23, 1360-1370	1	14
120	HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. *Journal of Molecular Neuroscience*, **2020**, 70, 981-992	3.3	13
119	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-□OTX2-SNAIL via PTEN inhibition. *Brain*, **2018**, 141, 1300-1319	11.2	13
118	Put away your microscopes: the ependymoma molecular era has begun. *Current Opinion in Oncology* , **2017**, 29, 443-447	4.2	13
117	MAP4K4 controlled integrin □ activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. *Oncotarget*, **2018**, 9, 23220-23236	3.3	13
116	Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia. *Proteomics*, **2017**, 17, 1600361	4.8	12
115	Measuring the optical characteristics of medulloblastoma with optical coherence tomography. *Biomedical Optics Express*, **2015**, 6, 1487-501	3.5	12
114	miR miR on the wall, who's the most malignant medulloblastoma miR of them all?. *Neuro-Oncology*, **2018**, 20, 313-323	1	12
113	Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). *Pediatric Blood and Cancer*, **2015**, 62, 1754-60	3	12
112	Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. *Neurosurgery*, **2013**, 60 Suppl 1, 57-63	3.2	12
111	Intracerebral malignant peripheral nerve sheath tumor in a child with neurofibromatosis Type 1 and middle cerebral artery aneurysm treated with endovascular coil embolization. *Journal of Neurosurgery: Pediatrics*, **2011**, 8, 346-52	2.1	12
110	Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. *Oncotarget*, **2016**, 7, 53881-53894	3.3	12
109	Principles and Practice of Pediatric Neurosurgery **2008**,		12

108	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. *Cell Reports Medicine*, **2020**, 1,	18	11
107	The molecular biology of medulloblastoma metastasis. *Brain Pathology*, **2020**, 30, 691-702	6	11
106	BMI1 is a therapeutic target in recurrent medulloblastoma. *Oncogene*, **2019**, 38, 1702-1716	9.2	11
105	The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. *Cell Stem Cell*, **2021**, 28, 488-501.e10	18	11
104	Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma. *Scientific Reports*, **2019**, 9, 13611	4.9	10
103	Somatostatin receptor subtype 2 (sst) is a potential prognostic marker and a therapeutic target in medulloblastoma. *Childs Nervous System*, **2013**, 29, 1253-62	1.7	10
102	Bmi1 overexpression in the cerebellar granule cell lineage of mice affects cell proliferation and survival without initiating medulloblastoma formation. *DMM Disease Models and Mechanisms*, **2013**, 6, 49-63	4.1	10
101	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2 Granule Neuron Precursor. *Cell Reports*, **2020**, 31, 107511	10.6	10
100	Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. *Journal of Neuro-Oncology*, **2019**, 141, 449-457	4.8	10
99	The Amazing and Deadly Glioma Race. *Cancer Cell*, **2015**, 28, 275-7	24.3	9
98	The AHR pathway represses TGF SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. *Scientific Reports*, **2020**, 10, 148	4.9	9
97	Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma. *Molecular Oncology*, **2018**, 12, 495-513	7.9	9
96	Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. *Acta Neuropathologica Communications*, **2020**, 8, 173	7.3	9
95	Neurotrophin Signaling in Medulloblastoma. *Cancers*, **2020**, 12,	6.6	9
94	Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. *ELife*, **2021**, 10,	8.9	9
93	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. *Neuro-Oncology*, **2020**, 22, 290-297	1	8
92	Modulating native GABA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death. *Journal of Neuro-Oncology*, **2019**, 142, 411-422	4.8	8
91	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. *Journal of Neuropathology and Experimental Neurology*, **2020**, 79, 437-447	3.1	8

90	5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. *Acta Neuropathologica*, **2018**, 135, 617-634	14.3	8
89	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. *Nature Communications*, **2020**, 11, 3627	17.4	8
88	Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. *Journal of Experimental Medicine*, **2020**, 217,	16.6	8
87	Artificial intelligence for automatic cerebral ventricle segmentation and volume calculation: a clinical tool for the evaluation of pediatric hydrocephalus. *Journal of Neurosurgery: Pediatrics*, **2020**, 1-8	2.1	8
86	Fall of the Optical Wall: Freedom from the Tyranny of the Microscope Improves Glioma Risk Stratification. *Cancer Cell*, **2016**, 29, 137-8	24.3	7
85	Incidence of metastatic disease and survival among patients with newly diagnosed primary CNS tumors in the United States from 2004-2013. *Journal of Cancer*, **2019**, 10, 3037-3045	4.5	7
84	Detection of Active Coronary Arterial Vasculitis Using Magnetic Resonance Imaging in Kawasaki Disease. *Circulation*, **2005**, 112,	16.7	7
83	Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup. *Journal of Molecular Diagnostics*, **2020**, 22, 957-966	5.1	7
82	The transcriptional landscape of Shh medulloblastoma. *Nature Communications*, **2021**, 12, 1749	17.4	7
81	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. *Nature Communications*, **2020**, 11, 1825	17.4	7
80	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 807-821	2.2	7
79	A functional genomics approach to identify pathways of drug resistance in medulloblastoma. *Acta Neuropathologica Communications*, **2018**, 6, 146	7.3	7
78	Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. *Journal of Neurosurgery: Pediatrics*, **2016**, 17, 298-302	2.1	6
77	Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma. *Frontiers in Pharmacology*, **2019**, 10, 698	5.6	6
76	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. *Cancer Medicine*, **2020**, 9, 447-459	4.8	6
75	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. *Cancer Discovery*, **2021**, 11, 1454-1467	24.4	6
74	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. *Journal of Neuro-Oncology*, **2019**, 145, 107-114	4.8	5
73	Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. *Neurosurgery*, **2017**, 64, 21-26	3.2	5

72	An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma. *EMBO Molecular Medicine*, **2019**, 11, e9830	12	5
71	Perspectives in pediatric neurosurgery. *Childs Nervous System*, **2000**, 16, 809-20	1.7	5
70	Abstract 4347: Medulloblastoma comprises four distinct diseases **2010**,		5
69	Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs		5
68	European genetic ancestry associated with risk of childhood ependymoma. *Neuro-Oncology*, **2020**, 22, 1637-1646	1	5
67	Spatial concordance of DNA methylation classification in diffuse glioma. *Neuro-Oncology*, **2021**, 23, 2054-2065	1	5
66	p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma. *Molecular Cancer Research*, **2019**, 17, 186-198	6.6	5
65	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. *Pediatric Neurology*, **2015**, 53, 238-242.e1	2.9	4
64	Anaplastic medulloblastoma in a child with Duchenne muscular dystrophy. *Journal of Neurosurgery: Pediatrics*, **2012**, 10, 21-4	2.1	4
63	Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. *PLoS ONE*, **2019**, 14, e0210665	3.7	3
62	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. *Cancer Research*, **2019**, 79, 2208-2219	10.1	3
61	Pediatric cancer genomics, a play rather than a portrait. *Nature Genetics*, **2015**, 47, 851-2	36.3	3
60	Early Lethality Due to a Novel Desmoplakin Variant Causing Infantile Epidermolysis Bullosa Simplex With Fragile Skin, Aplasia Cutis Congenita, and Arrhythmogenic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002800	5.2	3
59	Bioinformatics in neurosurgery. *Neurosurgery*, **2003**, 52, 723-30; discussion 730-1	3.2	3
58	Embryonal Brain Tumors **2015**, 127-138		3
57	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. *Neuro-Oncology*, **2021**,	1	3
56	Eye Movements and White Matter are Associated with Emotional Control in Children Treated for Brain Tumors. *Journal of the International Neuropsychological Society*, **2020**, 26, 978-992	3.1	2
55	CAR T cells for childhood diffuse midline gliomas. *Nature Medicine*, **2018**, 24, 534-535	50.5	2

54	Cancer: Drain the swamp to beat glioma. *Nature*, **2017**, 549, 460-461	50.4	2
53	Genome-wide methylation analysis. *Methods in Molecular Biology*, **2012**, 863, 303-17	1.4	2
52	Reply to J.C. Lindsey et al. *Journal of Clinical Oncology*, **2011**, 29, e348-e349	2.2	2
51	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.. *Nature Medicine*, **2022**,	50.5	2
50	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion. *PLoS ONE*, **2020**, 15, e0243272	3.7	2
49	GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 129-136	3.1	2
48	Subgroup and subtype-specific outcomes in adult medulloblastoma. *Acta Neuropathologica*, **2021**, 142, 859-871	14.3	2
47	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. *EMBO Molecular Medicine*, **2022**, e14552	12	2
46	Retraction Note: A homing system targets therapeutic T cells to brain cancer. *Nature*, **2019**, 567, 132	50.4	1
45	Reply to S.A. Milgrom et al. *Journal of Clinical Oncology*, **2020**, 38, 2212-2213	2.2	1
44	Pontine Infantile Glioma Simplified. *Cancer Cell*, **2017**, 32, 548-549	24.3	1
43	Transposase-driven rearrangements in human tumors. *Nature Genetics*, **2017**, 49, 975-977	36.3	1
42	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. *BMC Proceedings*, **2012**, 6,	2.3	1
41	Reply to J.C. Lindsey et al. *Journal of Clinical Oncology*, **2011**, 29, e347-e347	2.2	1
40	The biology of ependymomas and emerging novel therapies.. *Nature Reviews Cancer*, **2022**,	31.3	1
39	Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma-a multi-institutional study.. *Neuro-Oncology Advances*, **2021**, 3, vdab158	0.9	1
38	Basic Science of Pediatric Brain Tumors **2015**, 59-67		1
37	Postoperative isolated lower extremity supplementary motor area syndrome: case report and review of the literature. *Childs Nervous System*, **2020**, 36, 189-195	1.7	1

36	Left Ventricular Magnetic Resonance Imaging Strain Predicts the Onset of Duchenne Muscular Dystrophy-Associated Cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2020**, 13, e011526	3.9	1
35	Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. *Genome Medicine*, **2021**, 13, 103	14.4	1
34	Bioinformatic Strategies for the Genomic and Epigenomic Characterization of Brain Tumors. *Methods in Molecular Biology*, **2019**, 1869, 37-56	1.4	1
33	Radiation-induced intracranial aneurysm presenting with acute hemorrhage in a child treated for medulloblastoma. *Childs Nervous System*, **2021**, 37, 1387-1389	1.7	1
32	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. *Patient Preference and Adherence*, **2018**, 12, 2103-2110	2.4	1
31	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. *The Lancet Child and Adolescent Health*, **2021**, 5, 800-813	14.5	1
30	IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. *Neuro-Oncology*, **2019**, 21, ii93-ii93	1	0
29	Advanced cancer genetics in neurosurgical research. *Neurosurgery*, **2003**, 53, 1168-78; discussion 1178	3.2	0
28	Myocardial Parametric Mapping by Cardiac Magnetic Resonance Imaging in Pediatric Cardiology and Congenital Heart Disease.. *Circulation: Cardiovascular Imaging*, **2022**, CIRCIMAGING120012242	3.9	0
27	Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets. *Neuro-Oncology*, **2021**, 23, 718-731	1	0
26	Nailing a Fe-rocious form of cancer. *Science*, **2020**, 369, 250-251	33.3	0
25	Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer. *Nature Communications*, **2021**, 12, 5238	17.4	0
24	Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. *Nature Reviews Clinical Oncology*, **2019**, 16, 522-523	19.4	
23	Molecular Biology and Genetics of Medulloblastoma **2015**, 265-286		
22	Fingering the Correct Culprit: NonRANdom Target Selection for Therapy of Neuroblastoma. *Trends in Cancer*, **2015**, 1, 213-215	12.5	
21	Medulloblastoma and CNS Primitive Neuroectodermal Tumors. *Molecular Pathology Library*, **2015**, 121-142		
20	Medulloblastoma invading the transverse sinus: case report. *Journal of Neurosurgery: Pediatrics*, **2013**, 12, 325-7	2.1	
19	Pediatric Craniopharyngioma, Mixed Glioneuronal Tumors, and Atypical Teratoid/Rhabdoid Tumor **2010**, 62-74		

18	TMOD-25. LATENT SOX9-POSITIVE CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RELAPSE. *Neuro-Oncology*, **2021**, 23, vi220-vi221	1
17	STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY. *Neuro-Oncology*, **2021**, 23, vi26-vi26	1
16	Atypical Teratoid/Rhabdoid Tumors **2005**, 744-750	
15	Medulloblastomas **2018**, 1-27	
14	Medulloblastomas **2020**, 1997-2016	
13	Introduction. Pediatric brain tumor. *Neurosurgical Focus*, **2020**, 48, E1	4.2
12	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
11	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
10	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
9	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
8	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
7	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
6	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
5	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion **2020**, 15, e0243272	
4	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. *Neuro-Oncology*, **2022**, 24, i42-i42	1
3	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. *Neuro-Oncology*, **2022**, 24, i107-i107	1
2	MEDB-07. Long-term medical and functional outcomes of medulloblastoma survivors: a population-based, matched cohort study. *Neuro-Oncology*, **2022**, 24, i105-i105	1
1	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. *Neuro-Oncology*, **2022**, 24, i101-i102	1